F-star Therapeutics Gross Profit

F-star Therapeutics (FSTX) currently reports a gross profit of $21M as of September 2022. That compares with $3.8M in the prior-year period — up 452.7% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore F-star Therapeutics's gross profit history and peer comparisons.

F-star Therapeutics's gross profit increased from $3.8M to $21M — a 452.7% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

F-star Therapeutics's gross profit of $21M is lower than the Healthcare sector average of $66B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

F-star Therapeutics reported $21M in gross profit as of September 2022. That compares with $3.8M in the prior-year period — up 452.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for F-star Therapeutics, and consider following FSTX for alerts when major investors trade the stock.